JP2016508996A - 酸化ストレス及び／又は酸化還元不均衡の結果生じる病的状態の全身的治療のための組成物 - Google Patents

酸化ストレス及び／又は酸化還元不均衡の結果生じる病的状態の全身的治療のための組成物 Download PDF

Info

Publication number
JP2016508996A
JP2016508996A JP2015555120A JP2015555120A JP2016508996A JP 2016508996 A JP2016508996 A JP 2016508996A JP 2015555120 A JP2015555120 A JP 2015555120A JP 2015555120 A JP2015555120 A JP 2015555120A JP 2016508996 A JP2016508996 A JP 2016508996A
Authority
JP
Japan
Prior art keywords
compounds
composition
disease
cancer
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015555120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016508996A5 (enExample
Inventor
ロマニージョス，ガブリエル ゴジョン
ロマニージョス，ガブリエル ゴジョン
Original Assignee
ヌエヴァス オルタナティヴァス ナチュラルズ，エス．エー．ピー．アイ．デ シー．ブイ．
ヌエヴァス オルタナティヴァス ナチュラルズ，エス．エー．ピー．アイ．デ シー．ブイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/751,429 external-priority patent/US20130136725A1/en
Application filed by ヌエヴァス オルタナティヴァス ナチュラルズ，エス．エー．ピー．アイ．デ シー．ブイ．, ヌエヴァス オルタナティヴァス ナチュラルズ，エス．エー．ピー．アイ．デ シー．ブイ． filed Critical ヌエヴァス オルタナティヴァス ナチュラルズ，エス．エー．ピー．アイ．デ シー．ブイ．
Publication of JP2016508996A publication Critical patent/JP2016508996A/ja
Publication of JP2016508996A5 publication Critical patent/JP2016508996A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015555120A 2013-01-28 2014-01-28 酸化ストレス及び／又は酸化還元不均衡の結果生じる病的状態の全身的治療のための組成物 Pending JP2016508996A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/751,429 US20130136725A1 (en) 2002-06-19 2013-01-28 Compositions for systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US13/751,429 2013-01-28
PCT/MX2014/000029 WO2014116097A2 (es) 2013-01-28 2014-01-28 Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox

Publications (2)

Publication Number Publication Date
JP2016508996A true JP2016508996A (ja) 2016-03-24
JP2016508996A5 JP2016508996A5 (enExample) 2016-12-15

Family

ID=51228167

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015555120A Pending JP2016508996A (ja) 2013-01-28 2014-01-28 酸化ストレス及び／又は酸化還元不均衡の結果生じる病的状態の全身的治療のための組成物

Country Status (10)

Country Link
EP (1) EP2949332A4 (enExample)
JP (1) JP2016508996A (enExample)
KR (1) KR20160140331A (enExample)
CN (1) CN105228633A (enExample)
AU (1) AU2014210447A1 (enExample)
BR (1) BR112015017440A2 (enExample)
CA (1) CA2898596A1 (enExample)
HK (1) HK1217175A1 (enExample)
MX (1) MX2015009403A (enExample)
WO (1) WO2014116097A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY202502A (en) 2017-10-25 2024-05-01 4TEEN4 Pharmaceuticals GmbH Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
US20220062169A1 (en) * 2019-01-19 2022-03-03 Goldred Nanobiotech Co., Ltd. Ocular lens, pharmaceutical composition, and uses thereof
CA3171332A1 (en) 2020-03-16 2021-09-23 Andreas Bergmann Dpp3 in patients infected with coronavirus
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
WO2024126793A1 (en) 2022-12-15 2024-06-20 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for improvement of pulmonary function in critically ill patients
WO2024200862A1 (en) 2023-03-29 2024-10-03 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
WO2025247952A1 (en) * 2024-05-30 2025-12-04 Université De Fribourg Inhibition of cyanide overproduction for the therapy of down syndrome and nonketotic hyperglycinemia
WO2025248139A1 (en) 2024-05-31 2025-12-04 4TEEN4 Pharmaceuticals GmbH Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007063167A (ja) * 2005-08-30 2007-03-15 Fuso Pharmaceutical Industries Ltd 硫化水素塩を含有する消化器系疾患の予防／治療用組成物
US20090304819A1 (en) * 2002-06-19 2009-12-10 Gabriel Gojon-Romanillos Systemic Treatment of Pathological Conditions Resulting from Oxidative Stress and/or Redox Imbalance
JP2012532824A (ja) * 2009-07-08 2012-12-20 ホープ メディカル エンタープライゼズ，インコーポレイテッド ディービーエー ホープ ファーマシュティカルズ チオ硫酸ナトリウムを含有する薬学的組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148885A (en) 1973-09-25 1979-04-10 Institut Merieux Immunostimulant medicine
JPS59118709A (ja) 1982-12-27 1984-07-09 Suntory Ltd 効力を増強しかつ低毒化せしめた抗腫瘍組成物
DE3419686A1 (de) 1983-05-26 1984-11-29 T and R Chemicals, Inc., Clint, Tex. Verwendung einer zusammensetzung mit therapeutischer wirksamkeit
IL81166A (en) 1987-01-05 1990-03-19 Kaplan Ephraim Pharmaceutically active combination comprising an ionic vanadium compound and thiosulfate or sulfite compound and optionally selenium

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304819A1 (en) * 2002-06-19 2009-12-10 Gabriel Gojon-Romanillos Systemic Treatment of Pathological Conditions Resulting from Oxidative Stress and/or Redox Imbalance
JP2007063167A (ja) * 2005-08-30 2007-03-15 Fuso Pharmaceutical Industries Ltd 硫化水素塩を含有する消化器系疾患の予防／治療用組成物
JP2012532824A (ja) * 2009-07-08 2012-12-20 ホープ メディカル エンタープライゼズ，インコーポレイテッド ディービーエー ホープ ファーマシュティカルズ チオ硫酸ナトリウムを含有する薬学的組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Acid Armor", INTERNET, JPN6017026355, 30 September 2011 (2011-09-30), ISSN: 0003690221 *
"Tablets and Capsules: Special Delivery", INTERNET, JPN6017026357, 1 December 2010 (2010-12-01), ISSN: 0003690222 *

Also Published As

Publication number Publication date
MX2015009403A (es) 2017-07-04
CA2898596A1 (en) 2014-07-31
BR112015017440A2 (pt) 2017-07-11
EP2949332A4 (en) 2016-07-27
HK1217175A1 (zh) 2016-12-30
EP2949332A2 (en) 2015-12-02
WO2014116097A2 (es) 2014-07-31
CN105228633A (zh) 2016-01-06
AU2014210447A1 (en) 2015-08-20
WO2014116097A3 (es) 2014-12-04
KR20160140331A (ko) 2016-12-07

Similar Documents

Publication Publication Date Title
JP2016508996A (ja) 酸化ストレス及び／又は酸化還元不均衡の結果生じる病的状態の全身的治療のための組成物
US11786491B2 (en) Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
CN111683684B (zh) 用于治疗半胱胺敏感性病症的方法
CN104080339B (zh) 高生物利用度的零价硫的制备和组合物及其用途
US8389005B2 (en) Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US20130136725A1 (en) Compositions for systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US8361514B2 (en) Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
HK40038073A (en) Methods for the treatment of cysteamine sensitive disorders
HK40038073B (zh) 用於治疗半胱胺敏感性病症的方法
HK1262096A1 (en) Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171205